Syreon Corporation   Report issue

For profit Phase 1 Phase 3 Phase 4
Founded: Vancouver Canada (1995)

Organization Overview

First Clinical Trial
2015
NCT01762644
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Syreon Corporation

Active Ingredients

Drugs in Phase 4 Trials (3)

ertugliflozin (Steglatro) (1 trial)

metformin (glucophage) (1 trial)

sitagliptin (januvia) (1 trial)

Drugs in Phase 3 Trials (2)

cyclosporine (sandimmune) (1 trial)

omeprazole (prilosec) (1 trial)

Drugs in Phase 1 Trials (2)

fluticasone (cutivate) (1 trial)

rcs-01 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 3)

Diabetes Mellitus, Type 1 (Phase 3)

Osteoarthritis (Phase 1)

Osteoarthritis, Knee (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 4
  • # of Trial APIs: 7